Glowing needle could spot hidden breast tumors in real time
NCT ID NCT07339306
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new glowing needle that helps doctors find and sample very small abnormal areas inside breast ducts during surgery. The needle uses a special coating that lights up, making it easier to see and remove the right tissue. Researchers will compare how well this method works versus standard techniques in 300 women aged 18-75 who need breast duct surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Female patients aged 18-75 years. 2. Patients scheduled to undergo duct excision surgery. 3. Patients who are capable of providing written informed consent and adhering to the study protocols. Exclusion Criteria: 1. Pregnant or breastfeeding. 2. Patients who have known allergy to quantum-dot materials or localization needle components. 3. Patients with active hepatitis B or C infection with detectable viral load. 4. Patients with unstable cardiovascular disease (e.g., recent myocardial infarction, uncontrolled arrhythmia, NYHA class III-IV heart failure). 5. Patients with history of neurological or psychiatric disorders that may impair compliance (e.g., epilepsy, dementia). 6. Patients who concurrent participation in another interventional clinical trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast ductal carcinoma in situ are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The Fourth Affiliated Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could shedding pounds after breast cancer keep the disease away?
- 3D imaging could help surgeons remove all breast cancer in one go
- Fasting during chemo: a new way to boost treatment?
- Could a skin gel help fight breast cancer? early trial tests endoxifen
- CBD oil tested for breast cancer drug side effect
- Hot flash relief drug studied in breast cancer patients